On Thursday, the French drug manufacturer, Sanofi has confirmed that it has joined hands with Michael J. Fox Foundation for holding up trials for Parkinson's treatment. It has been reported that Michael J. Fox Foundation would be sponsoring for the phase I trial of the treatment.
Sanofi's AVE8112 drug would be involved in the trial. The drug has previously showed that it holds the potential to treat brain disorder Parkinson's disease. Parkinson's disease is a brain disorder in which a sufferer experiences shaking and walking difficulties. Besides this, mood swings are also experienced by the victims of the disease.
It has been informed that the trial would be initiated at the end of this year. The whole trial would take place in the US. The results of the trial would be owned by Michael J. Fox Foundation and would be shared with Sanofi.
The Chief Executive Officer of Michael J. Fox Foundation, Todd Sherer was reported as saying, "AVE8112 has shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson's disease. Groundbreaking collaborations with. Sanofi. help us . to improve the treatment of Parkinson's for patients today and in the future".
In the first phase of the study, the risk involved in providing the treatment to patients affected with Parkinson's disease would be gauged. Once all the risk involved in prescribing the drug has been examined, the researchers would then look at the benefits of prescribing the drug to patients.
It is estimated that millions of people in the US are affected with Parkinson's disease. However, no effective treatment is yet available. It is hoped that the findings of the researchers would help in finding effective treatment for the disorder.